StrategyIndustry Stakeholders React to Pelosi's Drug Pricing Plan
The Speaker's proposal generated ample discussion around its potential impact.
FinanceMedicaid Pharmacy Cost Trend Increases Despite Drop in Utilization
One of the most notable data points was the nearly flat rate for average claim cost, increasing 0.8%, compared to...
StrategyHHS OIG: Medicare Part D Drug Rebates 'Substantially' Reduced Spending Growth
Between 2011 and 2015, rebates for brand-name prescription drugs still increased $2 billion.
FinancePharma Cash Rolls Into Congress To Defend An Embattled Industry
The big contributions that lawmakers are getting signal that the pharmaceutical industry is building loyalty ahead of the 2020 elections.
FinanceSpecialty Drugs Account for 40% of Employers' Drug Costs
A survey found that specialty drugs have an outsized impact on employer prescription drug spending.
Clinical CareRWJBarnabas Develops ICU Pharmacy Team Model
A first-of-its-kind intensive training program gives non-specialist pharmacists confidence to deal with complex and critical medication issues for ICU patients.
StrategyDrugmakers Master Rolling Out Their Own Generics To Stifle Competition
Critics say authorized generics hurt long-term competition and often perversely increase costs, even in the short term.
FinanceSenate Finance Committee Passes Bipartisan Drug Pricing Bill
The bipartisan drug pricing bill passed the committee but faces industry opposition and uncertainty in the full Senate.
FinanceJudge Vacates HHS Rule That Would Require Drug Price Disclosure in TV Ads
The ruling is likely to be challenged at the United States Court of Appeals for the District of Columbia Circuit.
FinanceMedical Cost Trend Expected to Rise in 2020
After two flat years, the medical cost trend is expected to rise in 2020, according to PricewaterhouseCoopers.
FinanceNew York Bill Targets PBMs, Would Extend Medicaid FFS Program
Empire State lawmakers are considering legislation that would implement a fee-for-service program and effectively cut out PBMs.
FinancePharma M&A Activity Expected to Rise
Investment grade pharmaceutical companies continue to display a high capacity for M&A activity, according to a new Moody's report.